The table below shows Cogent Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$86.88M
-$66.51M
-$52.53M
-$39.52M
-$28.33M
-$11.37M
Capital expenditure
$449.00K
$547.00K
$70.00K
$1.10M
$441.00K
-
Investing cash flow
-$36.46M
$69.38M
$1.04M
$59.88M
-$441.00K
-
Dividends paid
-
-
-
-
COGT operating cash flow (10-K history)
Cogent Biosciences, Inc. reported operating cash flow of -$264.44M for fiscal year 2025. That is down 27.3% from -$207.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$25.84M (FY 2017) to -$264.44M. Figures come from the company's audited annual reports as filed with the SEC.